JAK1/2突变介导的PD-1阻断原发性耐药
本文探讨JAK1/2功能缺失突变与抗PD-1治疗原发性耐药的关系。研究在1/23例黑色素瘤和1/16例错配修复缺陷结肠癌患者的肿瘤活检中发现了JAK1/2失活突变,这两例均有高突变负荷但未对anti-PD-1治疗产生应答。48个人黑色素瘤细胞系中有2个携带JAK1/2突变,导致干扰素γ暴露后无法通过干扰素γ受体通路信号传导而缺乏PD-L1表达。TCGA中JAK1/2功能缺失改变与不良预后相关。作者提出JAK1/2功能缺失突变是缺乏反应性PD-L1表达和对干扰素γ应答的遗传机制,导致PD-1阻断治疗的原发性耐药。
要点
- 1/23例黑色素瘤和1/16例错配修复缺陷结肠癌患者的肿瘤活检中发现JAK1/2失活突变,均未对PD-1阻断治疗应答。
- 48个人黑色素瘤细胞系中2个携带JAK1/2突变,干扰素γ暴露后无法通过干扰素γ受体通路信号传导,导致PD-L1表达缺乏。
- TCGA中JAK1/2功能缺失改变与患者不良预后相关。
核心结论
- JAK1/2功能缺失突变是缺乏反应性PD-L1表达和对干扰素γ应答的遗传机制,导致PD-1阻断治疗的原发性耐药;携带此类肿瘤的患者不太可能对PD-1阻断治疗产生应答。
研究设计与样本
- 研究分析了接受PD-1阻断治疗的23例黑色素瘤患者和16例错配修复缺陷结肠癌患者的肿瘤活检,并检测了48个人黑色素瘤细胞系,同时利用TCGA数据评估JAK1/2功能缺失改变与预后的关系。
主要发现
- 1/23例黑色素瘤患者和1/16例错配修复缺陷结肠癌患者的肿瘤活检中发现了JAK1/2失活突变,这两例均有高突变负荷但未对anti-PD-1治疗产生应答。
- 48个人黑色素瘤细胞系中有2个携带JAK1/2突变,导致干扰素γ暴露后无法通过干扰素γ受体通路信号传导,从而缺乏PD-L1表达。
- TCGA中JAK1/2功能缺失改变与患者不良预后相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti-PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 patients with mismatch repair-deficient colon cancer treated with PD-1 blockade. Both cases had a high mutational load but did not respond to anti-PD-1 therapy. Two out of 48 human melanoma cell lines had JAK1/2 mutations, which led to a lack of PD-L1 expression upon interferon gamma exposure mediated by an inability to signal through the interferon gamma receptor pathway. JAK1/2 loss-of-function alterations in The Cancer Genome Atlas confer adverse outcomes in patients. We propose that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy. SIGNIFICANCE: A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188-201. ©2016 AACR.See related commentary by Marabelle et al., p. 128This article is highlighted in the In This Issue feature, p. 115.
引用
- Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2016. PMID: 27903500. doi:10.1158/2159-8290.CD-16-1223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。